The first $UNH hearing is getting underway.

Senate Finance Cmte chair Ron Wyden bashes 'failures of CEOs like Mr. Witty … who can't figure out how many people have had their data stolen.'

More on the pressures on UnitedHealth that brought us to today →

twitter.com/ddiamond/statu…

Brain biopsies on 'vulnerable' patients at Mount Sinai set off alarm bells at FDA

By ⁦Katherine Eban⁩ in ⁦STAT⁩. statnews.com/2024/05/01/bra…

lots of news✨ today --

FDA approves targeted treatment for most common brain tumor in kids

“We now have shown that you can develop drugs intentionally for children at the speed of biotech,” Sam Blackman said

endpts.com/fda-gives-acce…

CBER head Peter Marks noting at The Alliance for a Stronger FDA that the dialing back around gene therapies is being exacerbated by these challenges

In biggest-ever bet on using AI to design drugs, biotech heavyweights launch Xaira with $1B+ in backing - massive from Andrew Dunn and Ryan Cross the Science Boss endpts.com/in-biggest-eve…

.Joseph Ross, Joshua D. Wallach and others have an new paper in JAMA out today seeking more FDA transparency on the use of surrogate endpoints outside of oncology - endpts.com/researchers-se…

Gift link: theatlantic.com/health/archive…

(3/3)

We rely heavily on generic and biosimilar competition to evaporate the costs of expensive brand-name drugs.

But when a big PBM picks a winner before the competitive race to the bottom can even conclude, inflated prices become entrenched. Zach Brennan endpts.com/sandozs-humira…

Interview with FDA’s head of biosimilars:

FDA is ready to eliminate the interchangeability designation for biosimilars - endpts.com/fda-is-ready-t…

Drugmakers race to find alternative suppliers as US cracks down on Chinese biotech on.ft.com/3Jgw9PO

European Parliament adopts pharma legislative revamp by wide margin - endpts.com/european-parli…

Shipley was fiercely opposed to the Biosecure Act before BIO flipped...

Top lobbyist at BIO leaves as trade group grapples with US-China tensions - endpts.com/top-lobbyist-a…

Exclusive: Sanofi to close Dutch NK cell therapy biotech it acquired for $357M in ‘20

French pharma giant will shutter Kiadis, which had worked on “off-the-shelf” therapies for cancer, Covid

Sanofi had tried to divest the 27-year-old company

Endpoints News

endpts.com/exclusive-sano…

'1 recent Iqvia report found that wh/shifting to adalimumab biosimilars would save up to $6 b for the US health system, PBMs would lose up to 84% of profit—a major reason very few large payers have come on board. 7 biosimilars now employ price discounts of 80%' or >.
It's broken

Don't ever underestimate $ABBV's marketing skills. At last tally, there are now 9 knockoffs to Humira, and AbbVie retains 96% of the market. They are going to squeeze every last dollar out of it they can.
Zach Brennan covers the story.
endpts.com/over-a-year-af…

Over a year after biosimilars started competing, AbbVie still holds 96% of Humira market, report says - endpts.com/over-a-year-af…

#AACR24 USFDA Guidelines OCE Director Richard Pazdur says DTC advertising is 'a nightmare' and decries the 'egregious way' in which safety profiles are presented in DTC ads; says 'agency has to do something on that'

Foreign investors fled Chinese biotech after the pandemic. They still haven’t come back - endpts.com/foreign-invest…